This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 3-9 March 2024 and includes updates on SARS-CoV-2 variant classification, sexually transmitted infections, Psittacosis cases, product safety recall of InterPharma Sodium Chloride 0.9% 30ml linked to Ralstonia pickettii contamination, cholera and Middle East respiratory syndrome coronavirus (MERS-CoV).
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 11-17 February 2024, and includes updates on SARS-CoV-2 variant classification, diphtheria, chikungunya, dengue, influenza A(H5N1), a human case of co-infection with seasonal influenza A(H3N2) and avian influenza A(H10N5), Middle East respiratory syndrome coronavirus (MERS-CoV), and an overview of respiratory virus epidemiology in the EU/EEA.
In 2024, and as of 31 of January, approximately 10 000 CHIKVD cases and no deaths have been reported worldwide. A total of eight countries reported CHIKVD cases from the America (6) and Asia (2).